BioPharmSignal logoBioPharmSignal

Biotech News

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus

Enanta Pharmaceuticals (ENTA)Enanta PharmaceuticalsFDA / regulatory

MAVIRET® (Glecaprevir/Pibrentasvir) is the Only Treatment Approved in the European Union for Both Acute and Chronic Hepatitis C Virus (HCV) Infection Approval Allows Providers to Treat HCV Patients Immediately at Time of Diagnosis; Early Diagnosis and Treatment Help Reduce Transmission, Long-Term

Related news

ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

BMYBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

CRISCuris Inc2026-06-26 13:42 EST

Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split

INMBINmune Bio2026-06-25 11:00 EST

INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™

REGNRegeneron Pharmaceuticals2026-06-22 11:00 EST

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

SPROSpero Therapeutics2026-06-17 17:36 EST

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

BMYBMYBristol-Myers Squibb Company2026-06-01 10:55 EST

Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

IFRXInflarx NV2026-06-30 11:30 EST

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

HCWBHCW Biologics2026-07-23 12:00 EST

HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027

View all latest news

Enanta Pharmaceuticals

Small-Molecule Research Platform Enanta Pharmaceuticals discovers and develops oral small molecules for virology and immunology. Its portfolio applies structure-based drug design to targets that may support convenient, once-daily treatment. EDP-978 KIT Inhibitor EDP-978 is an oral KIT inhibitor in Phase 1 development for chronic...

Recent company news

ENTAEnanta Pharmaceuticals2026-06-23 09:10 EST

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus

ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

ENTAEnanta Pharmaceuticals2026-05-11 20:01 EST

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026

ENTAEnanta Pharmaceuticals2026-05-04 11:00 EST

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

Stock data

Close
13.34 USD
Market cap
349.81M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States